SCHEMBL1935409

SCHEMBL1935409

CNC(=O)c1c(-c2ccc(F)cc2)nn2c(C)cc(-c3cc(C(=O)N(c4ccccc4)C4CC4)ccc3C)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 6/20 0.38
CYP3A4 P08684 5/20 0.38
KCNH2 Q12809 3/20 0.36
NR1I2 O75469 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPK14 Q16539 4/20 0.34
KIT P10721 3/20 0.34
LCK P06239 2/20 0.34
KDR P35968 2/20 0.34
BRD4 O60885 1/20 0.33
ALDH1A1 P00352 2/20 0.33
TACR1 P25103 1/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
BTK Q06187 1/20 0.32
ABL1 P00519 1/20 0.31
CYP2D6 P10635 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK10 P53779 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2431980 0.94 CYP2C8 (0.38) CYP2C8CYP3A4KCNH2NR1I2MEN1
SCHEMBL2409322 0.87 CYP2C8 (0.38) CYP2C8CYP3A4KCNH2NR1I2MEN1
SCHEMBL1937059 0.84 CYP2C8 (0.36) CYP2C8CYP3A4KCNH2NR1I2MEN1
SCHEMBL1936681 0.84 CYP2C8 (0.40) CYP2C8CYP3A4KCNH2NR1I2MEN1
SCHEMBL2464836 0.80 CYP2C8 (0.60) CYP2C8CYP3A4KCNH2NR1I2MAPK14
SCHEMBL13241638 0.79 CYP2C8 (0.59) CYP2C8CYP3A4KCNH2NR1I2MAPK14
SCHEMBL1920481 0.76 CYP2C8 (0.65) CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL17530686 0.74 CYP3A4 (0.33) CYP2C8CYP3A4KCNH2
SCHEMBL2464955 0.74 CYP2C8 (0.60) CYP2C8CYP3A4KCNH2NR1I2MAPK14
SCHEMBL1936514 0.73 ALDH1A1 (0.45) CYP2C8CYP3A4KCNH2NR1I2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331502-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed